Wellington Management Group LLP Purchases New Holdings in Compass Therapeutics, Inc. $CMPX

Wellington Management Group LLP bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 222,505 shares of the company's stock, valued at approximately $423,000. Wellington Management Group LLP owned 0.16% of Compass Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares during the period. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $27,000. Mariner LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $30,000. Squarepoint Ops LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth approximately $35,000. Finally, ProShare Advisors LLC grew its stake in Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares during the period. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Stock Up 2.1%

NASDAQ:CMPX traded up $0.07 on Friday, hitting $3.44. The stock had a trading volume of 388,871 shares, compared to its average volume of 1,395,353. Compass Therapeutics, Inc. has a 52 week low of $1.27 and a 52 week high of $4.08. The business's fifty day moving average is $3.01 and its 200 day moving average is $2.47. The company has a market cap of $475.68 million, a PE ratio of -7.64 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Equities analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on CMPX. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Guggenheim increased their price target on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. Finally, Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. One research analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the stock. According to data from MarketBeat, Compass Therapeutics has a consensus rating of "Buy" and an average target price of $12.89.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.